N. Ziras

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)

John Souglakos, N. Ziras, Stylianos Kakolyris et al. · British Journal of Cancer · 2012 · 64 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial

Vassilis Georgoulias, Nikolaos Androulakis, Αthanasios Kotsakis et al. · Lung Cancer · 2007 · 46 citations

Medicine, Oncology, Pharmacology +9

Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG)

L. Vamvakas, A. Athanasiadis, Athanasios Karampeazis et al. · Critical Reviews in Oncology/Hematology · 2009 · 33 citations

Medicine, Geriatric Medicine, Oncology +15

A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer

Niki Karachaliou, N. Ziras, K. Syrigos et al. · Cancer Chemotherapy and Pharmacology · 2012 · 15 citations

Medicine, Oncology, Pharmacology +17

A multicenter randomized phase III study comparing paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as front-line treatment in patients with small cell lung cancer (SCLC)

D. Mavroudis, E. Papadakis, M. Veslemes et al. · Lung Cancer · 2000 · 14 citations

Medicine, Oncology, Pharmacology +9